CASI Pharmaceuticals, Inc.
CASIF
$0.10
$0.00-2.38%
OTC PK
| 12/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 134.86% | 71.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 134.86% | 71.38% | |||
| Cost of Revenue | 48.97% | 170.22% | |||
| Gross Profit | 423.09% | -20.20% | |||
| SG&A Expenses | 47.97% | 12.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 41.72% | 61.92% | |||
| Operating Income | -13.76% | -52.80% | |||
| Income Before Tax | -19.85% | -71.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.85% | -71.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.85% | -71.17% | |||
| EBIT | -13.76% | -52.80% | |||
| EBITDA | -17.37% | -64.64% | |||
| EPS Basic | 29.02% | -36.69% | |||
| Normalized Basic EPS | 28.89% | -2.71% | |||
| EPS Diluted | 29.02% | -36.82% | |||
| Normalized Diluted EPS | 28.89% | -2.71% | |||
| Average Basic Shares Outstanding | 68.84% | 25.22% | |||
| Average Diluted Shares Outstanding | 68.84% | 25.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||